Korro Bio Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Korro Bio Inc.
- Former names
- Frequency Therapeutics, Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Cambridge
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- KRRO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001703647
- EIN
- 47-2324450
Board of directors
- Since 2023
-
David L. Lucchino · Director · President and CEOSince 2023
-
Jean Francois Formela · DirectorSince 2023
-
Katharine Knobil · DirectorSince 2024
-
Nessan Bermingham · DirectorSince 2023
-
Rachel Meyers · DirectorSince 2023
-
Ram Aiyar · Director · President and CEOSince 2023
-
Timothy R. Pearson · DirectorSince 2023
Chief executives
Ram Aiyar
· President and CEO
Since November 2023
David L. Lucchino
· President and CEO
Until November 2023
· Former
Director election results
Annual meeting of June 10, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
81.5%
-
82.6%
Board connections
4 of this board's directors also sit on 10 other boards.
- via Ali Behbahani
- via Ali Behbahani
- via Ali Behbahani
- via Timothy R. Pearson
- via Jean Francois Formela
- via Katharine Knobil
- via Ali Behbahani
- via Ali Behbahani
- via Katharine Knobil
- via Ali Behbahani
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $20,792,250
- 12 purchases by 11 insiders
- Sold, last 12 months
- $5,698,848
- 33 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 14, 2026 | Jean Francois Formela Director | Open-market sale | −31,888 | $14.12 | $450,259 |
| Sep 14, 2026 | Jean Francois Formela Director | Open-market sale | −6,602 | $14.12 | $93,220 |
| Sep 11, 2026 | Dolan Oliver Officer (Senior Vice President, Finance) | Open-market sale | −5 | $13.72 | $69 |
| Sep 11, 2026 | Jean Francois Formela Director | Open-market sale | −8,450 | $13.99 | $118,216 |
| Sep 11, 2026 | Jean Francois Formela Director | Open-market sale | −1,750 | $13.99 | $24,483 |
| Sep 9, 2026 | Dolan Oliver Officer (Senior Vice President, Finance) | Open-market sale | −6 | $13.60 | $82 |
| Sep 8, 2026 | Dolan Oliver Officer (Senior Vice President, Finance) | Open-market sale | −7,347 | $13.51 | $99,286 |
| Aug 26, 2026 | Jean Francois Formela Director | Open-market sale | −249 | $13.96 | $3,476 |
| Aug 26, 2026 | Jean Francois Formela Director | Open-market sale | −51 | $13.96 | $712 |
| Aug 19, 2026 | Jean Francois Formela Director | Open-market sale | −23,584 | $14.00 | $330,176 |
| Aug 19, 2026 | Jean Francois Formela Director | Open-market sale | −4,884 | $14.00 | $68,376 |
| Aug 11, 2026 | Jean Francois Formela Director | Open-market sale | −1,775 | $13.96 | $24,779 |
| Aug 11, 2026 | Jean Francois Formela Director | Open-market sale | −368 | $13.96 | $5,137 |
| Aug 10, 2026 | Lynx1 Capital Management LP 10% owner | Open-market purchase | +1,462 | $13.19 | $19,279 |
| Aug 6, 2026 | Lynx1 Capital Management LP 10% owner | Open-market purchase | +5,222 | $11.40 | $59,530 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.